Table 1. Baseline characteristics.
| Characteristics | N = 288 |
| Age at diagnosis, median in years (range) | 51 (27–85) |
| Range, ages (years) | n (%) |
| <35 years | 22 (6.2) |
| 35–39 | 27 (11.1) |
| 40–49 | 78 (27.1) |
| 50–59 | 91 (31.6) |
| 60–69 | 50 (17.4) |
| ≥70 | 20 (6.6) |
| Menopausal status | n (%) |
| Premenopausal | 174 (60.4) |
| Postmenopausal | 114 (39.6) |
| Tumor size | n (%) |
| TX | 3 (1.0) |
| T1 | 7 (2.4) |
| T2 | 107 (37.1) |
| T3 | 71 (24.6) |
| T4 | 100 (34.7) |
| Lymph nodes | n (%) |
| N0 | 64 (22.2) |
| N1 | 124 (43) |
| N2 | 86 (29.8) |
| N3 | 14 (4.8) |
| TNM | n (%) |
| IIA | 49 (17) |
| IIB | 61 (21.2) |
| IIIA | 72 (25) |
| IIIB | 92 (32) |
| IIIC | 14 (4.8) |
| Histologic subtype | n (%) |
| Ductal | 274 (95.1) |
| Lobular | 6 (2.1) |
| Other | 8 (2.8) |
| Tumor grade | n (%) |
| G1 | 21 (7.3) |
| G2 | 131 (45.5) |
| G3 | 116 (40.3) |
| Unknown | 20 (6.9) |
| Estrogen receptor status | n (%) |
| Positive | 178 (61.8) |
| Negative | 110 (38.2) |
| Progesterone receptor status | n (%) |
| Positive | 142 (49.3) |
| Negative | 146 (50.7) |
| HER 2 | n (%) |
| Positive | 103 (35.7) |
| Negative | 184 (64) |
| Unknown | 1 (0.3) |
| Biological subtype (IHC4) | n (%) |
| Luminal A | 39 (13.5) |
| Luminal B, HER 2- | 80 (27.8) |
| Luminal B, HER 2+ | 57 (19.8) |
| Her 2 enriched | 46 (16) |
| Triple Negative | 62 (21.5) |
| Neoadjuvant Chemotherapy regimen | n (%) |
| Anthracycline-based only | 11 (3.8) |
| Taxanes-based only | 29 (10.1) |
| Anthracycline and taxane based | 248 (86.1) |
| Pathological response | n (%) |
| pCR | 89 (30.9) |
| No pCR | 199 (69.1) |
| Characteristics | N = 288 |
| Age at diagnosis, median in years (range) | 51 (27–85) |
| Range, ages (years) | n (%) |
| <35 years | 22 (6.2) |
| 35–39 | 27 (11.1) |
| 40–49 | 78 (27.1) |
| 50–59 | 91 (31.6) |
| 60–69 | 50 (17.4) |
| ≥70 | 20 (6.6) |
| Menopausal status | n (%) |
| Premenopausal | 174 (60.4) |
| Postmenopausal | 114 (39.6) |
| Tumor size | n (%) |
| TX | 3 (1.0) |
| T1 | 7 (2.4) |
| T2 | 107 (37.1) |
| T3 | 71 (24.6) |
| T4 | 100 (34.7) |
| Lymph nodes | n (%) |
| N0 | 64 (22.2) |
| N1 | 124 (43) |
| N2 | 86 (29.8) |
| N3 | 14 (4.8) |
| TNM | n (%) |
| IIA | 49 (17) |
| IIB | 61 (21.2) |
| IIIA | 72 (25) |
| IIIB | 92 (32) |
| IIIC | 14 (4.8) |
| Histologic subtype | n (%) |
| Ductal | 274 (95.1) |
| Lobular | 6 (2.1) |
| Other | 8 (2.8) |
| Tumor grade | n (%) |
| G1 | 21 (7.3) |
| G2 | 131 (45.5) |
| G3 | 116 (40.3) |
| Unknown | 20 (6.9) |
| Estrogen receptor status | n (%) |
| Positive | 178 (61.8) |
| Negative | 110 (38.2) |
| Progesterone receptor status | n (%) |
| Positive | 142 (49.3) |
| Negative | 146 (50.7) |
| HER 2 | n (%) |
| Positive | 103 (35.7) |
| Negative | 184 (64) |
| Unknown | 1 (0.3) |
| Biological subtype (IHC4) | n (%) |
| Luminal A | 39 (13.5) |
| Luminal B, HER 2- | 80 (27.8) |
| Luminal B, HER 2+ | 57 (19.8) |
| Her 2 enriched | 46 (16) |
| Triple Negative | 62 (21.5) |
| Neoadjuvant Chemotherapy regimen | n (%) |
| Anthracycline-based only | 11 (3.8) |
| Taxanes-based only | 29 (10.1) |
| Anthracycline and taxane based | 248 (86.1) |
| Pathological response | n (%) |
| pCR | 89 (30.9) |
| No pCR | 199 (69.1) |
pCR: pathological complete response